iSpecimen Past Earnings Performance
Past criteria checks 0/6
iSpecimen's earnings have been declining at an average annual rate of -16.4%, while the Healthcare Services industry saw earnings growing at 23.3% annually. Revenues have been growing at an average rate of 7.3% per year.
Key information
-16.4%
Earnings growth rate
47.5%
EPS growth rate
| Healthcare Services Industry Growth | 1.7% |
| Revenue growth rate | 7.3% |
| Return on equity | -202.0% |
| Net Margin | -91.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
iSpecimen Inc. (NASDAQ:ISPC) Looks Inexpensive After Falling 38% But Perhaps Not Attractive Enough
Jan 01
iSpecimen Inc. (NASDAQ:ISPC) Might Not Be As Mispriced As It Looks After Plunging 32%
Sep 13US$3.00: That's What Analysts Think iSpecimen Inc. (NASDAQ:ISPC) Is Worth After Its Latest Results
Aug 09Take Care Before Diving Into The Deep End On iSpecimen Inc. (NASDAQ:ISPC)
Jan 04Downgrade: Here's How This Analyst Sees iSpecimen Inc. (NASDAQ:ISPC) Performing In The Near Term
Aug 07Investors Still Aren't Entirely Convinced By iSpecimen Inc.'s (NASDAQ:ISPC) Revenues Despite 33% Price Jump
Apr 18iSpecimen names finance chief Tracy Curley as interim CEO
Sep 22iSpecimen Inc. (NASDAQ:ISPC) Analysts Just Slashed This Year's Estimates
Aug 10iSpecimen GAAP EPS of -$0.30 misses by $0.02, revenue of $2.3M misses by $0.55M
Aug 04iSpecimen Inc.'s (NASDAQ:ISPC) Intrinsic Value Is Potentially 69% Above Its Share Price
Mar 31iSpecimen: High Growth Marketplace At A Discount
Jul 07iSpecimen raises $18M via Nasdaq IPO
Jun 21Revenue & Expenses Breakdown
How iSpecimen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 10 | -10 | 11 | 4 |
| 30 Jun 24 | 11 | -10 | 12 | 4 |
| 31 Mar 24 | 9 | -12 | 13 | 4 |
| 31 Dec 23 | 10 | -11 | 13 | 4 |
| 30 Sep 23 | 10 | -10 | 13 | 3 |
| 30 Jun 23 | 10 | -11 | 14 | 3 |
| 31 Mar 23 | 11 | -10 | 14 | 3 |
| 31 Dec 22 | 10 | -10 | 13 | 3 |
| 30 Sep 22 | 10 | -10 | 13 | 2 |
| 30 Jun 22 | 10 | -9 | 12 | 2 |
| 31 Mar 22 | 11 | -7 | 11 | 2 |
| 31 Dec 21 | 11 | -9 | 10 | 2 |
| 30 Sep 21 | 11 | -9 | 9 | 2 |
| 30 Jun 21 | 11 | -8 | 8 | 2 |
| 31 Mar 21 | 9 | -7 | 6 | 1 |
| 31 Dec 20 | 8 | -5 | 6 | 1 |
| 30 Sep 20 | 7 | -4 | 5 | 1 |
| 31 Dec 19 | 4 | -5 | 5 | 1 |
| 31 Dec 18 | 4 | -5 | 4 | 1 |
Quality Earnings: ISPC is currently unprofitable.
Growing Profit Margin: ISPC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ISPC is unprofitable, and losses have increased over the past 5 years at a rate of 16.4% per year.
Accelerating Growth: Unable to compare ISPC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ISPC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (17.5%).
Return on Equity
High ROE: ISPC has a negative Return on Equity (-202.01%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 02:06 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
iSpecimen Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Constantine Davides | D. Boral Capital LLC. |
| Ashok Kumar | ThinkEquity LLC |